ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
ADMA Stock | USD 17.40 0.50 2.79% |
About 55% of ADMA Biologics' investor base is interested to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are impartial. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
Cash on Hand Utilized to Repay 30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMAs Total Debt to 75 Million, a 29 percent Reduction Furth
Read at gurufocus.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
ADMA Biologics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
ATRA | Atara Biotherapeutics | 14.80 | ||||
ETNB | 89bio | 12.94 | ||||
TNXP | Tonix Pharmaceuticals | 7.02 | ||||
MCRB | Seres Therapeutics | 6.98 | ||||
MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
STOK | Stoke Therapeutics | 3.36 | ||||
VXRT | Vaxart | 3.33 | ||||
CDTX | Cidara Therapeutics | 3.15 | ||||
SANA | Sana Biotechnology | 3.12 | ||||
IBIO | Ibio | 2.48 | ||||
BCRX | BioCryst Pharmaceuticals | 2.44 | ||||
AKBA | Akebia Ther | 2.23 | ||||
FATE | Fate Therapeutics | 1.20 | ||||
PLX | Protalix Biotherapeutics | 1.15 | ||||
ACLX | Arcellx | 0.44 | ||||
RCUS | Arcus Biosciences | 0.26 | ||||
INMB | INmune Bio | 0.45 | ||||
CRBU | Caribou Biosciences | 0.55 | ||||
PLRX | Pliant Therapeutics | 0.68 | ||||
ANTX | AN2 Therapeutics | 0.79 | ||||
XFOR | X4 Pharmaceuticals | 4.69 | ||||
ANEB | Anebulo Pharmaceuticals | 10.81 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stocks Directory Find actively traded stocks across global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |